HC Wainwright & Co. Maintains Neutral on Terns Pharma, Lowers Price Target to $5.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has maintained a Neutral rating on Terns Pharma (NASDAQ:TERN) but has lowered the price target from $8 to $5.5.
January 10, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Ed Arce maintains a Neutral rating on Terns Pharma but reduces the price target from $8 to $5.5.
The reduction in price target by HC Wainwright & Co. suggests a less optimistic outlook for Terns Pharma's stock price in the short term. This could lead to negative sentiment among investors and potentially result in a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100